Industries > Pharma > Global Cystic Fibrosis Therapeutics Market 2016-2026

Global Cystic Fibrosis Therapeutics Market 2016-2026

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

PUBLISHED: 02 November 2016
PAGES: 191
PRODUCT CODE: PHA0151

Clear
WOOCS 2.2.1
SKU: PHA0151 Categories: , ,

The latest report from business intelligence provider Visiongain offers comprehensive analysis of the global cystic fibrosis market. Visiongain expects the global cystic fibrosis market to grow at a CAGR of 16.7% from 2016 to 2021. The global cystic fibrosis market is estimated to reach $7.7bn by 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this 191-page report you will receive 113 tables, charts and graphs – all unavailable elsewhere.

The 191 page report provides clear detailed insight into the global cystic fibrosis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Cystic Fibrosis Therapeutics Market 2016-2026

Report Scope

Global Cystic Fibrosis market forecasts from 2016-2026

• Cystic Fibrosis submarket forecasts from 2016-2026 covering:
– Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
– Protein Transcription Modulators
– Pancreatic Enzyme Products (PEP)
– Other therapies

Individual drug revenue forecasts from 2016-2026 by pharmacological classes:

– Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators:
• Orkambi
• Kalydeco
• VX-661 + ivacaftor
• Second corrector/VX-661/ivacaftor

– Protein Transcription Modulators
• Pulmozyme
• QR-010
• Translarna

– Pancreatic Enzyme Products (PEP)
• Ceron

– Other therapies
• Cayston
• TOBI

• Revenue forecasts from 2016-2026 and discussion of relevant trends and developments in the leading national cystic fibrosis market

• Analysis of the key factors driving growth in the global, regional and country level of the Cystic Fibrosis Market from 2016-2026

Patent and clinical trials information of the marketed and pipeline products for cystic fibrosis

• The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe

• Discussion on selected leading companies marketing and developing cystic fibrosis drugs:
– Vertex Pharmaceuticals
– Roche
– AbbVie
– Gilead Sciences
– Novartis

Visiongain’s study is intended for anyone requiring commercial analyses for the Cystic Fibrosis Market and leading companies. You find data, trends and predictions.

Buy our report today: Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Cystic Fibrosis Therapeutics Market 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Global Cystic Fibrosis Therapeutics Market 2016-2026


Latest Pharma news

Visiongain Publishes Companion Diagnostics (CDx) Market Report 2021-2031

Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy.

17 June 2021

READ

Visiongain Publishes Cellular Immunotherapy Market Report 2021-2031

Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.

15 June 2021

READ

Visiongain Publishes Gene Therapy R&D Market Report 2021-2031

Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.

14 June 2021

READ

Visiongain Publishes Next Generation Sequencing Market Report 2021-2031

Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.

04 June 2021

READ

Categories